Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-09-09 00:05 |
Cantargia: nya data från två kliniska studier ger starkt stöd för nadunolimab e…
|
Swedish | 114.5 KB | ||
| 2024-09-09 00:05 |
Cantargia: new data from two clinical studies strongly support nadunolimab effi…
|
English | 113.8 KB | ||
| 2024-08-28 12:25 | Swedish | 3.3 MB | |||
| 2024-08-28 12:25 | English | 3.3 MB | |||
| 2024-08-27 10:55 |
Cantargia reports timelines for nadunolimab clinical trials in leukemia and tri…
|
English | 110.2 KB | ||
| 2024-08-27 10:55 |
Cantargia rapporterar tidslinjer för kliniska studier av nadunolimab vid leukem…
|
Swedish | 111.0 KB | ||
| 2024-08-09 10:10 |
Cantargia rapporterar framsteg och starka biomarkörsdata i fas I kliniska studi…
|
Swedish | 107.4 KB | ||
| 2024-08-09 10:10 |
Cantargia reports progress and strong biomarker data from phase I clinical tria…
|
English | 107.0 KB | ||
| 2024-07-22 08:30 |
Cantargia rapporterar en organisatorisk förändring
|
Swedish | 98.8 KB | ||
| 2024-07-22 08:30 |
Cantargia reports organisational change
|
English | 98.0 KB | ||
| 2024-06-14 11:05 |
Cantargia rapporterar fortsatta framsteg i pågående klinisk fas I-studie med CA…
|
Swedish | 106.8 KB | ||
| 2024-06-14 11:05 |
Cantargia reports further progress in ongoing phase 1 clinical trial with CAN10
|
English | 107.0 KB | ||
| 2024-06-11 07:30 |
Cantargia strengthen management team with the appointment of Ton Berkien as Chi…
|
English | 104.9 KB | ||
| 2024-06-11 07:30 |
Cantargia stärker ledningsgruppen genom rekryteringen av Ton Berkien som Chief …
|
Swedish | 105.9 KB | ||
| 2024-05-23 23:01 |
Cantargia presents new positive clinical data on nadunolimab counteracting chem…
|
English | 112.8 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
